A new mode of action of ellipticine, a molecule known for its anti-cancer properties has been identified by researchers from the CEA, CNRS, Inserm, Institut Curie and Joseph Fourier-University Grenoble 1. They selected derivatives of this molecule capable of specifically targeting the CK2 protein, a protein kinase dysregulated in many cancers, and have demonstrated the antitumor potential of these derivatives. This work, published online by the journal Cancer Research, opens new perspectives for the design of future cancer drugs.
Thesis presented June 24, 2008 by Émilie Vassal.
Thesis presented June 11, 2008 by Xavier Fonrose. PhD thesis available in Intranet as a pdf file.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.